



Pergamon

Tetrahedron Letters 40 (1999) 5705–5707

TETRAHEDRON
LETTERS

New application of the Julia olefination for the synthesis of Tyr-Gly *E*-alkene and carba isostere pseudopeptides

Cécile Charrier, Laurent Ettouati * and Joelle Paris


*Université Claude Bernard Lyon I, Institut des Sciences Pharmaceutiques et Biologiques,
Laboratoire de Chimie Thérapeutique, 8 avenue Rockefeller, F-69373 Lyon cedex 08, France*

Received 5 May 1999; accepted 8 June 1999

Abstract

A new application of the Julia olefination to the synthesis of TyrΨ[*E*-CH=CH]Gly and TyrΨ[CH₂CH₂]Gly pseudopeptides is described via condensation of tertibutyl bromoacetate on tyrosine-derived β-ketosulfone and subsequent reductive desulfonation. © 1999 Elsevier Science Ltd. All rights reserved.

The replacement of the amide bond linkage within peptides is a classical strategy for the study of biologically active peptides and for the preparation of peptide bonds resistant to proteolysis.¹ Among the different described amide bond surrogates, the non-hydrolysable *E*-ethylenic isosteres mimic the three-dimensional structure of the amide bond.² Several synthetic routes of *E*-olefin pseudopeptides are described in the literature.³ Among them, the Julia olefination has been applied in this context.⁴ We would like to disclose herein our results on a new application of the Julia olefination to the synthesis of TyrΨ[*E*-CH=CH]Gly and TyrΨ[CH₂CH₂]Gly dipeptides according to Scheme 1.




Scheme 1.

Lygo has been the first person to investigate this strategy but has failed to obtain the *E*-olefin isostere of Ala-Gly dipeptide.⁵ *N*^α-Boc-Tyr(*t*Bu)-OMe **4**⁶ was first transformed into the β-ketosulfone **5**⁷ by alkylation with two equivalents of the di-lithio anion of methyl phenyl sulfone at -78°C as described by Lygo (Scheme 2). It was necessary to use an excess of the anion to obtain complete conversion of the starting compound **4**. Condensation of tertibutyl bromoacetate onto β-ketosulfone **5** was achieved with potassium carbonate in DMF for 6 h in 78% yield. Next we turned our attention to the conversion of the β-ketosulfone **6** into the corresponding *E*-alkene isostere **9**. Lygo did not succeed in the transformation of

* Corresponding author. Fax: +33 4 78 77 71 58; e-mail: ettouati@univ-lyon1.fr

the corresponding Ala-Gly ketosulfone ethyl ester into the *E*-alkene product using sodium borohydride reduction followed by reductive desulfonation with sodium amalgam at -10°C , but instead obtained the fully reduced methyl ester. However, we found that a *t*Bu protecting group for the ester **2** is required for the efficient reductive desulfonation of **3**. In this way, the β -ketosulfone tertibutyl ester **6** was transformed in the same conditions into the *E*-alkene isostere **9** in 40% yield. However, we improved the yield by isolating the intermediate alcohols **7** and then reducing the acetylated diastereomers **8** to obtain the dipeptide isostere **9** in 54% overall yield from **6**.



Scheme 2. Reagents: (a) PhSO₂CHLi₂, THF, 0°C 30 min then -30°C 3 h; (b) BrCH₂COOtBu, K₂CO₃, DMF, rt, 6 h; (c) NaBH₄, MeOH, -10°C 3 h; (d) Ac₂O, DMAP, pyridine, rt, 3 h; (e) Na/Hg, MeOH, Na₂HPO₄, -10°C , 2 h; (f) H₂, Pd/C, EtOH 95°, rt, 20 h

Finally, catalytic hydrogenation of *E*-alkene **9** gave the fully protected carbapeptide **10** in 90% yield.⁸

In conclusion, we have shown that a new application of Julia olefination methodology allows for the efficient synthesis of TyrΨ[*E*-CH=CH]Gly and TyrΨ[CH₂CH₂]Gly pseudoisostere in five (29.5% overall yield) and six steps, respectively, from Boc-protected tyrosine methyl ester. Furthermore, synthesis of XaaΨ[CH=CH]Xbb pseudoisosteres would be feasible through condensation of β -ketosulfone **1** with α -substituted bromoester **2**.⁹

Acknowledgements

Dr. B. Lygo is gratefully acknowledged for helpful information.

References

1. Spatola, A. In *Chemistry and Biochemistry of Amino acids, Peptides and Protein*; Weinstein, B. Ed.; Marcel Dekker: New York, 1983; Vol. 7, pp. 267–357.
2. Hann, M. M.; Sammes, P. G.; Kennewell, P. D.; Taylor, J. B. *J. Chem. Soc., Perkin Trans. 1* **1982**, 307–314.
3. Devadder, S.; Verheyden, P.; Jaspers, H. C. M.; Van Binst, G.; Tourwé, D. *Tetrahedron Lett.* **1996**, *37*, 703–706, and references cited therein. For recent references, see: Kranz, M.; Kessler, H. *Tetrahedron Lett.* **1996**, *37*, 5359–5362; Wipf, P.; Henninger, C. *J. Org. Chem.* **1997**, *62*, 1586–1587. Toda, A.; Masse, C. G.; Knight, B. S.; Stavropoulos, P.; Paneck, J.

- S. *J. Am. Chem. Soc.* **1997**, *119*, 6040–6047; Aoyama, H.; Mimura, N.; Ohno, H.; Fujii, N.; Ibuka, T. *J. Org. Chem.* **1998**, *63*, 7053–7061.
4. Spaltenstein, A.; Carpino, F.; Miyake, F.; Hopkins, P. B. *J. Org. Chem.* **1987**, *52*, 3759–3766.
5. Lygo, B. *Synlett* **1992**, 793–795.
6. Compound **4** was prepared by standard procedures from either the corresponding commercial N^α -Boc-protected acid or the free amine methyl ester.
7. All compounds gave satisfactory ^1H NMR and FTIR data. Compound **9**: $[\alpha]_D +2.6$ (c 0.57, CHCl_3), glassy solid. IR (film, ν cm^{-1}): 3360, 2932, 1713, 1503, 1391, 1237, 1162. ^1H NMR (300 MHz, CDCl_3 , δ ppm): 1.32 (s, 9H, *t*Bu), 1.39 (s, 9H, *t*Bu), 1.43 (s, 9H, *t*Bu), 2.78 (d, $J=6.2$ Hz, 2H, CH_2), 2.94 (d, $J=6.6$ Hz, 2H, CH_2), 4.37 (m, 1H, CH α or NH), 4.46 (m, 1H, NH or CH α), 5.50 (dd, $J=15.8$ Hz and 5.1 Hz, 1H, =CH), 5.62 (m, 1H, =CH), 6.90 (d, $J=8.3$ Hz, 2H, 2CH ar), 7.05 (d, $J=8.3$ Hz, 2H, 2CH ar).
8. Compound **10** was found enantiomerically pure by C18 RP-HPLC analysis after complete deprotection ($\text{TFA}/\text{CH}_2\text{Cl}_2$) and derivatization with GITC (see: Nimura, N.; Ogura, H.; Kinoshita, T. *J. Chromatography* **1980**, *202*, 375–379).
9. Gante, J.; Anlauf, U.; Wetzol, R. In *Peptides, Proceedings of the Twenty-Second European Peptide Symposium*; Schneider; Eberle, A. N., Eds.; ESCOM: Leiden, 1992; pp. 605–607.